In a recent study published in PLOS ONE, researchers found a potential cause of long-lasting symptoms experienced by COVID-19 patients, often referred to as long-haulers.
They found an antibody that shows up weeks after initial infection and attacks and disrupts a key regulator of the immune system.
The study is from the University of Arkansas. One author is John Arthur, M.D., Ph.D.
As many as 30% of COVID-19 patients experience lingering fatigue, brain fog and shortness of breath.
The cause of long COVID-19 has eluded scientists, but the team’s discovery sheds important new light on the molecular-level mechanisms behind it.
The antibody creates problems for the immune system by attacking the angiotensin-converting enzyme 2 (ACE2). The ACE2 enzyme helps regulate the body’s response to the virus by metabolizing a peptide that activates the immune system.
The attacking antibody interferes with ACE2’s work, which makes the antibody a prime suspect for the long-lasting illness.
In the study, the team tested plasma or serum for ACE2 antibodies in 67 patients with known SARS-CoV-2 (the virus that causes COVID-19) infection and 13 with no history of infection.
In 81% of blood samples from patients in Arkansas and Oklahoma with a history of COVID-19, the samples had the antibody that attacked the ACE2.
In participants with no history of COVID-19, no antibodies were created to attack the ACE2 enzyme.
The team says if they show that the whole hypothesis is right, that this interference of ACE2 really does cause long COVID, then it opens up many potential treatments.
If their next steps confirm that this antibody is the cause of long COVID symptoms, there are medications that should work to treat them.
If you care about COVID, please read studies about men with low testosterone more likely to die from COVID-19 and findings of prostate cancer drugs hold potential for treating COVID-19.
For more information about COVID and your health, please see recent studies about autopsy study shows how COVID-19 damages the brain and results showing that cholesterol-lowering drugs may reduce COVID-19 death in these people.
Copyright © 2021 Knowridge Science Report. All rights reserved.
